Drug Profile
Rheumatoid arthritis HSP-65-derived peptide
Alternative Names: Rheumatoid arthritis heat shock protein-derived peptideLatest Information Update: 01 Mar 2000
Price :
$50
*
At a glance
- Originator Acambis
- Developer Acambis; University of Bristol
- Class Antirheumatics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 01 Mar 2000 Discontinued-Preclinical for Rheumatoid arthritis in United Kingdom (Unknown route)
- 03 Mar 1998 New profile
- 03 Mar 1998 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)